Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Blood (2024) 144 (Supplement 1): 4206.

https://doi.org/10.1182/blood-2024-200239

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4939.

https://doi.org/10.1182/blood-2024-193963

Published: 2024

Journal Articles

Outcomes of Paediatric Acute Promyelocytic Leukaemia in the UK

Aditi Vedi, Irum Memon, Else Van Risjik, Urmila Uparkar, Geofffrey Shenton, Amélie Trinquand, Katherine Clesham, Vanessa Mclelland, Helen Jane Campbell, Katharine Patrick, Lyndsey Thompson, Susan Baird, Philip Connor, Beki James

Blood (2023) 142 (Supplement 1): 2862.

https://doi.org/10.1182/blood-2023-188993

Published: 2023

Journal Articles

Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)

Blood (2022) 140 (Supplement 1): 8987–8988.

https://doi.org/10.1182/blood-2022-162475

Published: 2022

Journal Articles

Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure

Blood (2022) 140 (Supplement 1): 2408–2410.

https://doi.org/10.1182/blood-2022-162863

Published: 2022

Journal Articles

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

Blood (2022) 140 (Supplement 1): 10352–10354.

https://doi.org/10.1182/blood-2022-164879

Published: 2022

Journal Articles

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 3268–3270.

https://doi.org/10.1182/blood-2022-162565

Published: 2022

Journal Articles

Blinatumomab for infant acute lymphoblastic leukemia

Katherine Clesham, Vasudha Rao, Jack Bartram, Philip Ancliff, Sara Ghorashian, David O’Connor, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Michelle Cummins, Andrea Malone, Katharine Patrick, Denise Bonney, Beki James, Brenda Gibson, Ajay Vora

Blood (2020) 135 (17): 1501–1504.

https://doi.org/10.1182/blood.2019004008

Published: 2020

Journal Articles

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Vasudha Rao, MD, Katherine Clesham, Jack Luke Bartram, MD, Phil Ancliff, Sara Ghorashian, FRCPath, PhD, David O'Connor, Vesna Pavasovic, Anupama Rao, MD, Sujith Samarasinghe, Carole Cairns, David Marks, David Taussig, PhD MRCP, FRCPath, Ajay Vora, MD

Blood (2018) 132 (Supplement 1): 5201.

https://doi.org/10.1182/blood-2018-99-117051

Published: 2018

Journal Articles

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

Selina J Chavda, MBBS BSc MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Pavlina Mesiri, MSc, Nicholas Counsell, Jaimal Kothari, FRCPath, Antonia Bird, Ciaran Mariner, Anastasia Chew, MBBS, MRCP, FRCPATH, Katherine Clesham, MBBS, Sally Moore, BSc, FRPATH, FRCP, MBBS, Laura Percy, MBBS, MRCP, FRCPATH, Ali Rismani, MBBS, Shirley D'Sa, Rakesh Popat, Neil Rabin, Kwee L Yong

Blood (2016) 128 (22): 3465.

https://doi.org/10.1182/blood.V128.22.3465.3465

Published: 2016

Journal Articles

Outcomes With Rituximab Monotherapy Versus R-CHOP In Post-Transplant Lymphoproliferative Disease Arising After Solid Organ Transplant: A Multicentre UK Study

David Burns, Katherine Clesham, Joanna Haughton, Michelle Lannon, Hayder Hussein, Jennifer Marsh, Martin Rowe, Anne L Lennard, Roderick J Johnson, Kate Cwynarski, Sridhar Chaganti

Blood (2013) 122 (21): 3043.

https://doi.org/10.1182/blood.V122.21.3043.3043

Published: 2013

NARROW

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Outcomes of Paediatric Acute Promyelocytic Leukaemia in the UK

Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)

Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Blinatumomab for infant acute lymphoblastic leukemia

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

Outcomes With Rituximab Monotherapy Versus R-CHOP In Post-Transplant Lymphoproliferative Disease Arising After Solid Organ Transplant: A Multicentre UK Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only